{"id":"csa-pg-ophthalmic-gel","safety":{"commonSideEffects":[{"rate":null,"effect":"Ocular irritation or burning"},{"rate":null,"effect":"Conjunctival hyperemia"},{"rate":null,"effect":"Foreign body sensation"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Cyclosporine A is a calcineurin inhibitor that reduces T-cell activation and inflammatory cytokine production. The PG (propylene glycol) formulation enhances ocular penetration and residence time, allowing sustained immunosuppressive effects on the ocular surface to reduce inflammation and increase tear production in dry eye disease.","oneSentence":"CsA-PG is a cyclosporine A prodrug formulated as an ophthalmic gel that suppresses local immune responses in the eye to treat dry eye disease.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:45:36.504Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Dry eye disease (keratoconjunctivitis sicca)"}]},"trialDetails":[{"nctId":"NCT06942793","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Treatment With CsA-PG Ophthalmic Gel in Dry Eye Patients","status":"NOT_YET_RECRUITING","sponsor":"Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.","startDate":"2025-05-20","conditions":"Dry Eye Disease","enrollment":396}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"CsA-PG Ophthalmic Gel","genericName":"CsA-PG Ophthalmic Gel","companyName":"Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.","companyId":"zhaoke-guangzhou-ophthalmology-pharmaceutical-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"CsA-PG is a cyclosporine A prodrug formulated as an ophthalmic gel that suppresses local immune responses in the eye to treat dry eye disease. Used for Dry eye disease (keratoconjunctivitis sicca).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}